We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Perlegen and Merck to Work on Whole-Genome Analysis

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Perlegen and Merck to Work on Whole-Genome Analysis "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Perlegen Sciences, Inc. has announced that it will assist Merck & Co., Inc. in conducting a high-density whole genome analysis of 1,000 individuals with important clinical characteristics.

Using Affymetrix GeneChip® technology including the GeneChip® Human Mapping 500K Array Set, Perlegen scientists will assay up to 675,000 genetic variations (also called single nucleotide polymorphisms or SNPs) in DNA samples provided by Merck.

Perlegen will utilize its high capacity SNP genotyping capability to rapidly generate extremely dense DNA variation data that can be integrated with other large datasets Merck has generated by molecular profiling clinically important tissue samples internally.

“We are pleased to work with Merck scientists in identifying DNA variations that may underlie biological mechanisms important to their drug discovery efforts,” Brad Margus, CEO of Perlegen.

“It was an honor to have been selected by Merck for this important project.”